title: Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
abstract: Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares. Complete response, although rare, has been reported. The authors reported herein a case of complete biochemical and radiological remission of advanced unresectable HCC with lymph node metastasis and tumoral portal vein thrombosis treated by 5 months therapy with sorafenib followed by adjuvant Yttrium-90 radioembolization. At 12 months follow-up, there is no evidence of HCC recurrence.
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Dario
authors.initials: D
authors.lastname: Lorenzin
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Riccardo
authors.initials: R
authors.lastname: Pravisani
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Cosimo Alex
authors.initials: CA
authors.lastname: Leo
authors.affiliation: 2 General Surgery, AUSL Umbria 2 , Italy .|3 School of Biotechnologies, University of Perugia , Italy .
authors.forename: Walter
authors.initials: W
authors.lastname: Bugiantella
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Giorgio
authors.initials: G
authors.lastname: Soardo
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Alessia
authors.initials: A
authors.lastname: Carnelutti
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Baccarani
authors.initials: B
authors.lastname: Umberto
authors.affiliation: 1 General Surgery and Transplantation Unit, University Hospital "S. Maria della Misericordia," Udine, Italy .
authors.forename: Andrea
authors.initials: A
authors.lastname: Risaliti
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D059248:Chemoradiotherapy; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011169:Portal Vein / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D000077157:Sorafenib; D013927:Thrombosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D009536:Niacinamide; D000077157:Sorafenib
keywords: Yttrium-90; advanced hepatocellular carcinoma; radioembolization; sorafenib